-
Mashup Score: 15Posters - ESMO Congress 2024 - 2 month(s) ago
Paulo G. Bergerot (Duarte, United States of America) Paulo G. Bergerot (Duarte, United States of America) Cristiane D. Bergerot (Sao Paulo, Brazil) Jonas R. Silva (Sao Paulo, Brazil) Marcos Vinicius França (Sao Paulo, Brazil) Paulo Sergio Moraes Lages (Brasilia, Brazil) William H. Fuzita (Manaus, Brazil) Andressa C. Azeredo (Porto Alegre, Brazil, RS) Narjust Florez (Boston, United States of America) Kathryn H. Schmitz (Pittsburgh, United States of America) Enrique Soto Perez de Celis (Ciudad de Mexico,
Source: cslide.ctimeetingtech.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Paulo G. Bergerot discussing Exercise for People with Advanced Cancer at WCLC24 - OncoDaily - 2 month(s) ago
Paulo G. Bergerot discussing Exercise for People with Advanced Cancer at WCLC24 / cancer, Laila Agrawal, Laloni Heather Law, Maria Petrill, Melinda Hsu,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: Paulo G. Bergerot discussing Exercise for People with Advanced Cancer at WCLC24 https://t.co/B9aln5TihD @PauloBergerot @IA…
-
-
Mashup Score: 10Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient | American Society of Clinical Oncology Educational Book - 4 month(s) ago
The standard treatment paradigm for muscle invasive bladder cancer has been neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. However, efforts are ongoing to personalize treatment by incorporating biomarkers to better guide treatment selection. In addition, bladder preservation strategies are aimed at avoiding cystectomy in well-selected patients. Similarly, in the metastatic urothelial cancer space, the standard frontline treatment option of platinum-based chemotherapy has changed with the availability of data from EV-302 trial, making the combination of enfortumab vedotin (EV) and pembrolizumab the preferred first-line treatment option. Here, we examine the optimization of treatment intensity and sequencing, focusing on the challenges and opportunities associated with EV/pembrolizumab therapy, including managing toxicities and exploring alternative dosing approaches. Together, these articles provide a comprehensive overview of contemporary strategies in bladder
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
3- Optimizing tx for Your pt w Urothelial Cancer Potential biomarkers to guide management of #bladdercancer The changing landscape of frontline tx for pts w mUC #BladderCancer @ASCO #ASCOEdBook Gregory Hemenway @MattGalsky @GhataliaPooja 👉 https://t.co/qXSJ5gD4Ut https://t.co/vFkrPu29OK
-
-
Mashup Score: 33Physical activity and checkpoint inhibition: association with toxicity and survival - 5 month(s) ago
AbstractBackground. Although animal experiments suggest beneficial effects of physical activity (PA) on antitumor immunity, little is known about the effec
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet-
RT @ArndtVogel: Physical activity & checkpoint inhibition: association with toxicity & survival @JNCI_Now https://t.co/pgL5KkfH2C 🇩🇰 RWD,…
-
-
Mashup Score: 22Program Guide – ASCO Meeting Program Guide - 6 month(s) ago
Regina Barragán Carrillo City of Hope Comprehensive Cancer Center, Duarte, CA Regina Barragán Carrillo, Nazli Dizman, Hedyeh Ebrahimi, Luis A Meza, Paulo Gustavo Bergerot, Tanya B. Dorff, Joann Hsu, Zeynep Busra Zengin, Nicholas Salgia, Alex Chehrazi-Raffle, Abhishek Tripathi, Daniela V. Castro, Benjamin Mercier, Gregory Caporaso, Keehoon Lee, Sumanta Kumar Pal City of Hope Comprehensive Cancer Center, Duarte, CA, The University of Texas MD Anderson Cancer Center, Houston, TX, Yale University School of
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet-
I’m so happy and honored for being part in this study lead by @montypal’s team superstar @ReginaBarCar on the impact of #latino ethnicity on the #GutMicrobiome composition of pts w renal cell cancer #ASCO24 @ASCO 👉 https://t.co/vYtjg9rqmL https://t.co/xzvtfXxYup
-
-
Mashup Score: 32Program Guide – ASCO Meeting Program Guide - 6 month(s) ago
Nazli Dizman The University of Texas MD Anderson Cancer Center, Houston, TX Nazli Dizman, Hedyeh Ebrahimi, Regina Barragán Carrillo, Luis A Meza, Paulo Gustavo Bergerot, Tanya B. Dorff, Joann Hsu, Zeynep Busra Zengin, Daniela V. Castro, Alex Chehrazi-Raffle, Abhishek Tripathi, Jeffrey M. Trent, Motomichi Takahashi, Kentaro Oka, Seiya Higashi, Gregory Caporaso, Keehoon Lee, Sumanta Kumar Pal The Univ ersity of Texas MD Anderson Cancer Center, Houston, TX, City of Hope Comprehensive Cancer Center, Duarte,
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet-
Outstanding study by @montypal’s team rockstar @NazliDizman on the Impact of CBM588 on #GutMicrobiome composition & dysbiosis in pts receiving frontline ICI combos for metastatic #renalcell carcinoma #ASCO24 @ASCO 👉 https://t.co/UVsPGcnYfP https://t.co/SYuvnVfYc3
-
-
Mashup Score: 24Program Guide – ASCO Meeting Program Guide - 6 month(s) ago
Speaker: Eric Daniel Tetzlaff, PA-C, MHS Speaker: Cardinale B. Smith, MD, PhD, FASCO Speaker: Vonetta Michelle Williams MD, PhD Speaker: Raymond U. Osarogiagbon, MBBS, FACP Speaker: Lauren Victoria Ghazal, PhD, APRN-BC Speaker: Julian C. Hong, MD, MS Speaker: Dawn L. Hershman MD, MS, FASCO Presenter: Bea Bakshi MBBS, BSc Speaker: Danielle Sara Bitterman, MD Speaker: Raymond U. Osarogiagbon, MBBS, FACP Speaker: Cardinale B. Smith MD, PhD, FASCO Speaker: Deborah Mayer PhD, RN, AOCN,
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet-
➡️ Abstract Titles Just Released #ASCOQLTY23 We’re thrilled to share the results of our ExIO study and discuss the potential impact of this strategy on the quality of care in #oncology. @crisbergerot @NarjustFlorezMD @EnriqueSoto8 @ASCO 👉 https://t.co/64y6WSi2mz https://t.co/WlTlRvj5xn
-
-
Mashup Score: 23Program Guide – ASCO Meeting Program Guide - 6 month(s) ago
Speaker: Eric Daniel Tetzlaff, PA-C, MHS Speaker: Cardinale B. Smith, MD, PhD, FASCO Speaker: Vonetta Michelle Williams MD, PhD Speaker: Raymond U. Osarogiagbon, MBBS, FACP Speaker: Lauren Victoria Ghazal, PhD, APRN-BC Speaker: Julian C. Hong, MD, MS Speaker: Dawn L. Hershman MD, MS, FASCO Presenter: Bea Bakshi MBBS, BSc Speaker: Danielle Sara Bitterman, MD Speaker: Raymond U. Osarogiagbon, MBBS, FACP Speaker: Cardinale B. Smith MD, PhD, FASCO Speaker: Deborah Mayer PhD, RN, AOCN,
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet-
➡️ Abstract Titles Just Released #ASCOQLTY23 We’re thrilled to share the results of our ExIO study and discuss the potential impact of this strategy on the quality of care in #oncology. @crisbergerot @NarjustFlorezMD @EnriqueSoto8 @ASCO 👉 https://t.co/64y6WSi2mz https://t.co/WlTlRvj5xn
-
-
Mashup Score: 23Program Guide – ASCO Meeting Program Guide - 6 month(s) ago
Speaker: Eric Daniel Tetzlaff, PA-C, MHS Speaker: Cardinale B. Smith, MD, PhD, FASCO Speaker: Vonetta Michelle Williams MD, PhD Speaker: Raymond U. Osarogiagbon, MBBS, FACP Speaker: Lauren Victoria Ghazal, PhD, APRN-BC Speaker: Julian C. Hong, MD, MS Speaker: Dawn L. Hershman MD, MS, FASCO Presenter: Bea Bakshi MBBS, BSc Speaker: Danielle Sara Bitterman, MD Speaker: Raymond U. Osarogiagbon, MBBS, FACP Speaker: Cardinale B. Smith MD, PhD, FASCO Speaker: Deborah Mayer PhD, RN, AOCN,
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet-
➡️ Abstract Titles Just Released #ASCOQLTY23 We’re thrilled to share the results of our ExIO study and discuss the potential impact of this strategy on the quality of care in #oncology. @crisbergerot @NarjustFlorezMD @EnriqueSoto8 @ASCO 👉 https://t.co/64y6WSi2mz https://t.co/WlTlRvj5xn
-
-
Mashup Score: 33Physical activity and checkpoint inhibition: association with toxicity and survival - 7 month(s) ago
AbstractBackground. Although animal experiments suggest beneficial effects of physical activity (PA) on antitumor immunity, little is known about the effec
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet-
RT @ArndtVogel: Physical activity & checkpoint inhibition: association with toxicity & survival @JNCI_Now https://t.co/pgL5KkfH2C 🇩🇰 RWD,…
-
Thrilled to present our study at #ESMO24 @myESMO! We assessed #QOL impact for patients in #PalliativeCare who participated in our #ExerciseOncology study #PallOnc @fitaftercancer @crisbergerot @NarjustFlorezMD @EnriqueSoto8 👉 https://t.co/6K772uBUTW https://t.co/5WhFTiFpgg